A real-world study in Northwest China confirms Palbociclib plus endocrine therapy (ET) benefits HR+/HER2- metastatic breast cancer (MBC) patients, aligning with global findings.

Nanovaccines leverage nanotechnology to enhance the delivery of cancer antigens to immune cells, potentially overcoming the limitations of traditional cancer vaccines.

Real-world data of the KEYNOTE-522 regimen shows a significantly improved pathologic complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC).

INOVIO plans to submit a Biologics License Application (BLA) to the FDA for INO-3107 by mid-2025, seeking priority review for recurrent respiratory papillomatosis.

CRISPR-based therapies are entering a new phase with the first approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.

A nine-month-old infant in Duncan, B.C., diagnosed with leukemia, is undergoing CAR-T therapy as part of a clinical trial in Vancouver.

PSMA PET-CT imaging proves more accurate than standard CT and bone scans in detecting prostate cancer metastasis, with 92% accuracy versus 65%.

BioNTech's BNT-327, a bispecific antibody targeting PD-L1 and VEGF, has demonstrated positive early results in patients with triple-negative breast cancer.

UCB's Bimzelx (bimekizumab-bkzx) demonstrated sustained complete skin clearance in 67.7% of patients with moderate-to-severe plaque psoriasis after five years of treatment, according to Phase III clinical trial data.

Scientists at the Netherlands Cancer Institute have identified an enzyme that converts LIXTE's lead compound LB-100 into its active form endothall, potentially serving as a biomarker for patient response prediction.

Kodiak Sciences has successfully enrolled over 250 patients in its GLOW2 Phase 3 trial of tarcocimab tedromer for diabetic retinopathy, with topline data expected in Q1 2026.

Protagonist Therapeutics and Johnson & Johnson's oral peptide icotrokinra achieved 63.5% clinical response rate in ulcerative colitis patients at Week 12, significantly outperforming placebo in the Phase 2b ANTHEM-UC study.

RedHill Biopharma plans to initiate an innovative Phase 2 study of RHB-204 in MAP-positive Crohn's disease patients, representing a paradigm shift in treatment by targeting a suspected cause rather than symptoms.

UroGen Pharma has submitted a new drug application for UGN-102 ahead of schedule, with FDA review underway and a target decision date of June 13, 2025.

A landmark study by NYU Langone Health reveals kidney transplant recipients with type 2 diabetes who take GLP-1 agonists experience 49% lower risk of organ failure and 31% reduced mortality within five years.

Life Molecular Imaging and St. Teresa's Hospital announce Florbetaben (18F) Injection (Neuraceq®) will be available in Hong Kong by March 2025, enhancing early and accurate diagnosis of Alzheimer's disease.

The U.S. monoclonal antibodies market is expected to grow from $94.09 billion in 2025 to $284.90 billion by 2034, driven by rising prevalence of chronic diseases and expanding therapeutic applications beyond oncology.

Akari Therapeutics (NASDAQ: AKTX) has successfully priced a $7.6 million private placement financing round, with funds directed toward its spliceosome inhibitor payload ADC technology platform.

UFlex has received FDA approval for its recycled polyethylene (rPE) in food packaging, marking the first such authorization for an Indian company in food-contact recycling.

Kalaris Therapeutics and AlloVir have finalized their merger, with the combined entity operating under the Kalaris name and trading on Nasdaq as KLRS, led by CEO Andrew Oxtoby.